WAVE Life Sciences Ltd (FRA:1U5)
€ 12.8 -0.1 (-0.78%) Market Cap: 1.89 Bil Enterprise Value: 1.62 Bil PE Ratio: 0 PB Ratio: 13.52 GF Score: 41/100

Q2 2022 WAVE Life Sciences Ltd Earnings Call Transcript

Aug 11, 2022 / 12:30PM GMT
Release Date Price: €2.59 (+11.71%)
Operator

Good morning, and welcome to the Wave Life Sciences Second Quarter 2022 Financial Results and Business Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded and webcast.

I'll now turn the call over to Kate Rausch, VP of Investor Relations and Corporate Affairs at Wave Life Sciences. Please go ahead.

Kate Rausch
Wave Life Sciences Ltd. - Head of IR

Thank you, operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's second quarter 2022 financial results. Joining me today are Dr. Paul Bolno, President and Chief Executive Officer; Dr. Mike Panzara, Chief Medical Officer and Head of Therapeutics Discovery and Development; Dr. Chandra Vargeese, Chief Technology Officer and Head of Platform Discovery Sciences; and Kyle Moran, Chief Financial Officer. The press release issued this morning and the slide presentation to accompany this webcast are available on the Investors section of our website,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot